BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine

▴ BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine.
BHV3000-310 is a double-blind, randomized trial evaluating the safety and efficacy of rimegepant in the acute treatment of migraine.

BioShin Limited announced today that the first patients were enrolled in its regional multi-center study, BHV3000-310, being conducted in China and Korea. BHV3000-310 is a double-blind, randomized trial evaluating the safety and efficacy of rimegepant in the acute treatment of migraine.

Karl Lintel, M.D., Chief Executive Officer of BioShin commented, “We are very pleased to have started enrollment in study BHV300-310. Rimegepant was launched in March 2020 in the USA where its differentiated profile with a rapid onset of action and long-half life is being recognized by patients and providers as an important new treatment option for people suffering from migraine. There has been a lack of innovative treatment for more than two decades for the acute treatment of migraine, and we believe that rimegepant will meet the unmet medical needs of migraine patients in the Asia-Pacific region, as it is doing in the USA."

"Migraine is a common and serious disease that affects human health," said Professor Yu Shengyuan, Chief of Neurology at the PLA General Hospital. “According to the results of the World Health Organization (WHO) 2013 Global Burden of Disease Survey published in The Lancet, migraine is the third most common human disease and the first cause of disability in under the 50s, and we need new, effective and safe treatment options to help improve the lives of our patients. I believe that rimegepant will be a welcome treatment option for patients and I am encouraged that we are moving one step closer to bringing rimegepant to patients in Asia with the start of study BHV3000-310.”

Professor Byung-Kun Kim, an investigator at the Nowon Eulji Medical Center in Korea announced, "We are very happy that Nowon Eulji Center has enrolled the first subjects in the BHV 3000-310 study, and we expect that the results of this study will bring new hope to migraine patients suffering from migraine.”

About Migraine
Migraine is a chronic and debilitating disorder characterized by recurrent attacks lasting four to 72 hours with multiple symptoms, including typically one-sided, pulsating headaches of moderate or severe pain intensity that are associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia). Migraine affects approximately 9% of the adult population in China, comprising 80 TO 90 million adults. The total indirect cost to Chinese society from lost productivity is estimated to be about USD$40 billion. Comorbid conditions associated with migraine include depression, anxiety, and cardiovascular disease.

About BHV-3000 (Rimegepant)
Rimegepant (Nurtec™ ODT) is a calcitonin gene-related peptide (CGRP) receptor antagonist that is being developed for acute migraine treatment. Rimegepant was approved by the US FDA for the acute treatment of migraine in February 2020, and an sNDA has been accepted by the US FDA for the preventive treatment of migraine.

The CGRP receptor is located within pain-signaling pathways, intracranial arteries, and mast cells and its activation is thought to play a causal role in migraine pathophysiology. Treatment with a CGRP receptor antagonist is believed to relieve migraine through the possible mechanisms of

1) blocking neurogenic inflammation,

2) decreasing artery dilation, and 3) inhibiting pain transmission. This new approach to the treatment of migraine avoids the cardiovascular effects produced by active vasoconstriction associated with the current standard triptan therapy (non-selective 5-HTlB/lD agonists (e.g., sumatriptan [Imitrex™]).

About the BHV3000-310 study
The BHV3000-310 study is an Asia-Pacific multicenter Phase III clinical study. It is a double-blind, randomized, placebo-controlled, safety, and efficacy trial of BHV-3000 (rimegepant) for the treatment of migraine in the acute phase. The study obtained a CTA from China’s NMPA on March 20, 2020, and the IND from the Korean FDA on Jun 29, 2020.

About BioShin

BioShin Limited, a privately-held biopharmaceutical company with offices in Shanghai, is advancing the Biohaven clinical portfolio in the Asia-Pacific region. BioShin holds rights to the Biohaven portfolio for all of the Asia-Pacific Region, including Australia and New Zealand, excluding Japan. BioShin’s neuro innovation portfolio includes the US FDA-approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and myeloperoxidase inhibition for multiple system atrophy and amyotrophic lateral sclerosis.

About Biohaven

Biohaven Pharmaceutical Holding Company Ltd (Biohaven) is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, Rutgers, and ALS Biopharma LLC and. Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors. Biohaven's common shares are listed on the New York Stock Exchange and traded under the ticker symbol BHVN. 

Tags : #BioShin #AsiaPacific #rimegepant #BHV3000 #ClinicalTrial #MigraneTreatment #Biohaven #China #Korea #KarlLintel

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024